Biomedical Engineering Reference
In-Depth Information
[36] Hanson LR , Frey WH II . Strategies for intranasal delivery of therapeutics for the preven-
tion and treatment of neuroAIDS . J Neuroimmune Pharmacol 2007 ; 2 : 81 - 6 .
[37] Chapat S , Frey V , Claperon N , Bouchaud C , Puisieux F , Couvreur
P , et al . Efficiency
of liposomal ATP in cerebral ischemia: bioavailability features .
Brain
Res
Bull
1991 ; 26 : 339 - 42 .
[38] Illum L . Transport of drugs from the nasal cavity to the central nervous system . Eur J
Pharm Sci 2000 ; 11 : 1 - 18 .
[39] Michael IU , Norbert V , Renaat K . The biopharmaceutical aspects of nasal mucoadhesive
drug delivery . J Pharm Pharmacol 2001 ; 53 : 3 - 22 .
[40] Sharifi R , Knoll LD , Smith J , Kramolowsky E . Leuprolide acetate (30 -mg depot every
four months) in the treatment of advanced prostate cancer . Urology 1998 ; 51 : 271 - 6 .
[41] DeVane GW , Gangrade BK , Wilson R , Loy RA . Optimal pregnancy outcome in a mini-
mal - stimulation
in vitro
fertilization program . Am J Obstet Gynecol 2000 ; 183 : 309 - 13 .
[42] Frey WH II . Bypassing the blood -brain barrier to deliver therapeutic agents to the brain
and spinal cord . Drug Deliv Tech 2002 ; 2 : 46 - 9 .
[43] Thorne RG , Pronk GJ , Padmanabhan V , Frey WH II . Delivery of insulin-like growth fac-
tor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following
intranasal administration . Neuroscience 2004 ; 127 : 481 - 96 .
[44] Ross TM , Martinez PM , Renner JC , Thorne RG , Hanson LR , Frey WH II . Intranasal
administration of interferon beta bypasses the blood-brain barrier to target the central
nervous system and cervical lymph nodes: a noninvasive treatment strategy for multiple
sclerosis . J Neuroimmunol 2004 ; 151 : 66 - 77 .
[45] Dragphia R , Caillaud C , Manicom R , Pavirani A , Kahn A , Poenaru L . Gene delivery into
the central nervous system by nasal instillation in rats . Gene Ther 1995 ; 2 : 418 - 23 .
[46] Mygind N , Anggard A . Anatomy and physiology of the nose pathophysiologic altera-
tions in allergic rhinitis . Clin Rev Allergy 1984 ; 2 : 173 - 88 .
[47] Schipper NGM , Verhoef JC , Merkus FWHM . The nasal mucociliary clearance: relevance
to nasal drug delivery . Pharm Res 1991 ; 8 : 807 - 14 .
[48] Mathison S , Nagilla R ,
Kompella UB . Nasal route for direct delivery of solutes to the
central nervous system: fact or fiction? J Drug Targeting 1998 ; 5 : 415 - 41 .
[49] Brand G . Olfactory/trigeminal interactions in nasal chemoreception . Neurosci Biobehav
Rev 2006 ; 30 : 908 - 17 .
[50] Brodbelt A , Stoodley M . CSF pathways: a review . Br J Neurosurg 2007 ; 21 : 510 - 20 .
[51] Mygind N . Upper airway: structure function and therapy . In: Moren F , Newhouse
MT , Dolovich MB , editors. Aerosols in medicine, principles, diagnosis and therapy .
Amsterdam : Elsevier ; 1985 . p. 1 - 20 .
[52] Dhanda DS , Frey WH II , Leopold D , Kompella UB . Nose-to-brain delivery: approaches
for drug deposition in the human olfactory epithelium . Drug Deliv Technol 2005 ; 5 : 6 4 - 7 2 .
[53] Thorne RG , Frey WH II . Delivery of neurotrophic factors to the brain: pharmacokinetic
considerations . Clin Pharmacokinet 2001 ; 40 : 907 - 46 .
[54] Lewis JL , Nikula KJ , Novak R , Dahl AR . Comparative localization of carboxylesterase
in F344 rat, beagle dog, and human nasal tissue . Anat Rec 1994 ; 239 : 55 - 64 .
[55] Krishna NSR , Getchell TV , Awasthi YC , Dhooper N , Getchell ML
. Age and gender -
related trends in the expression of glutathione
S
- transferases in human nasal mucosa .
Ann Otol Rhin Laryng 1995 ; 104 : 812 - 22 .
[56] Aceto A , Ilio CD , Angelucci S , Longo V , Gervasi PG , Federici G . Glutathione transfer-
ases in human nasal mucosa . Arch Toxicol 1989 ; 63 : 427 - 31 .
[57] Lee VH . Enzymatic barriers to peptide and protein absorption . Crit Rev Ther Drug Carr
Syst 1988 ; 5 : 69 - 97 .
Search WWH ::
Custom Search